of data
support
quality of product
Stock Locations
- New Jersey, USA
- Czech Republic, EU
- Mumbai, India
* Stock subject to availability.
Documentation
Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.
71675-87-1Amisulpride EP Impurity E
● In Stock
| Catalogue No.: | VL6330003 |
|---|---|
| CAS No.: | 71675-87-1 |
| Mol. Formula: | C10H13NO5S |
| Mol. Weight: | 259.28 g/mol |
Additional information on CAS 71675-87-1
Parent drug
AmisulprideIUPAC Name
4-Amino-5-(ethylsulfonyl)-2-methoxybenzoic acidPharmacopoeial Synonyms
N/AOther Synonyms
2-Methoxy-4-amino-5-ethylsulfonylbenzoic AcidSmiles
O=C(O)C1=CC(S(=O)(CC)=O)=C(N)C=C1OCInChI
InChI=1S/C10H13NO5S/c1-3-17(14,15)9-4-6(10(12)13)8(16-2)5-7(9)11/h4-5H,3,11H2,1-2H3,(H,12,13)Shipping Condition
Ambient TemperatureCharacterization Data (Included)
HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, and Structure Elucidation Report (SER).Additional Characterization Data
QNMR, D2O Exchange, 13C NMR, 13C APT, COSY NMR, NOESY NMR, 15N NMR, HSQC NMR, HMQC NMR, and HMBC NMR. These are available upon request and may be free or subject to additional charges.Description
Amisulpride EP Impurity E is a well-characterized reference material that meets stringent regulatory standards set by USP, EMA, JP, and BP. It plays a key role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial production of Amisulpride. It is an impurity of amisulpride. Amisulpride is a compound that lies in the category of substituted benzamide, it antagonizes the dopamine receptors. It is highly D2 and D3 receptor-selective. In high doses, it’s a dopaminergic blocker and in low doses it facilitates dopaminergic transmission. It is used in the treatment of patients with schizophrenia. It is an impurity of amisulpride. Amisulpride is a compound that lies in the category of substituted benzamide, it antagonizes the dopamine receptors. It is highly D2 and D3 receptor-selective. In high doses, it’s a dopaminergic blocker and in low doses it facilitates dopaminergic transmission. It is used in the treatment of patients with schizophrenia.
References
Coukell, Allan J., et al. “Amisulpride.” CNS Drugs, vol. 6, no. 3, Sept. 1996, pp. 237–56, https://doi.org/10.2165/00023210-199606030-00006.Request a Quote
"*" indicates required fields
![1,8-Diazabicyclo[5.4.0]undec-7-ene](https://veeprho.com/wp-content/uploads/2022/07/1-8-Diazabicyclo5B5.4.05Dundec-7-ene.png "1,8-Diazabicyclo[5.4.0]undec-7-ene")
